Vancomycin (Lyophilisate, Powder) Instructions for Use
ATC Codes
A07AA09 (Vancomycin)
J01XA01 (Vancomycin)
Active Substance
Vancomycin (Rec.INN registered by WHO)
Clinical-Pharmacological Group
Antibiotic of the glycopeptide group
Pharmacotherapeutic Group
Systemic antibacterial agents; other antibacterial agents; antibacterial agents of glycopeptide structure
Pharmacological Action
An antibiotic of the glycopeptide group. It exerts a bactericidal effect. It disrupts the synthesis of the bacterial cell wall, the permeability of the cytoplasmic membrane, and the synthesis of RNA. It is active against gram-positive bacteria: Staphylococcus spp. (including strains producing penicillinase and methicillin-resistant strains), Streptococcus spp., Enterococcus spp., Corynebacterium spp., Listeria spp., Actinomyces spp., Clostridium spp. (including Clostridium difficile).
No cross-resistance with antibiotics of other groups has been noted.
Pharmacokinetics
It is widely distributed in most body tissues and fluids. It penetrates the blood-brain barrier poorly, but permeability increases with meningeal inflammation. It crosses the placental barrier. Plasma protein binding is 55%. The T1/2 is 4-11 hours. 80-90% is excreted in the urine, a small amount is excreted in the bile.
Indications
Severe infectious and inflammatory diseases caused by pathogens sensitive to vancomycin (in cases of intolerance or ineffectiveness of therapy with other antibiotics, including penicillins or cephalosporins): sepsis, endocarditis (as monotherapy or as part of combined antibiotic therapy), pneumonia, lung abscess, meningitis, bone and joint infections, skin and soft tissue infections. Pseudomembranous colitis caused by Clostridium difficile.
ICD codes
| ICD-10 code | Indication |
| A04.7 | Enterocolitis due to Clostridium difficile |
| A40 | Streptococcal sepsis |
| A41 | Other sepsis |
| G00 | Bacterial meningitis, not elsewhere classified |
| I33 | Acute and subacute endocarditis |
| J15 | Bacterial pneumonia, not elsewhere classified |
| J85 | Abscess of lung and mediastinum |
| L02 | Cutaneous abscess, furuncle and carbuncle |
| L03 | Cellulitis |
| L08.0 | Pyoderma |
| L08.8 | Other specified local infections of skin and subcutaneous tissue |
| M00 | Pyogenic arthritis |
| M86 | Osteomyelitis |
| T79.3 | Posttraumatic wound infection, not elsewhere classified |
| ICD-11 code | Indication |
| 1A04 | Intestinal infections caused by Clostridium difficile |
| 1B70.1 | Streptococcal cellulitis of the skin |
| 1B70.2 | Staphylococcal cellulitis of the skin |
| 1B70.Z | Bacterial cellulitis or lymphangitis caused by unspecified bacterium |
| 1B75.0 | Furuncle |
| 1B75.1 | Carbuncle |
| 1B75.2 | Furunculosis |
| 1B75.3 | Pyogenic skin abscess |
| 1B7Y | Other specified pyogenic bacterial infections of skin or subcutaneous tissue |
| 1C44 | Non-pyogenic bacterial infections of skin |
| 1D01.0Z | Bacterial meningitis, unspecified |
| 1G40 | Sepsis without septic shock |
| BB4Z | Acute or subacute endocarditis, unspecified |
| CA40.0Z | Bacterial pneumonia, unspecified |
| CA43.Z | Abscess of lung or mediastinum, unspecified |
| EA50.3 | Staphylococcal scarlet fever |
| EB21 | Pyoderma gangrenosum |
| FA1Z | Infectious arthropathies, unspecified |
| FB84.Z | Osteomyelitis or osteitis, unspecified |
| NF0A.3 | Posttraumatic wound infection, not elsewhere classified |
| 1A1Y | Other specified bacterial foodborne intoxications |
| XN0SE | Clostridium difficile |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
Lyophilisate, Powder
It is administered by intravenous drip. For adults – 500 mg every 6 hours or 1 g every 12 hours. To avoid collaptoid reactions, the infusion duration should be at least 60 minutes. For children – 40 mg/kg/day, each dose should be administered over at least 60 minutes. In patients with impaired renal excretory function, the dose is reduced taking into account the CC values.
Depending on the etiology of the disease, Vancomycin can be taken orally. For adults, the daily dose is 0.5-2 g in 3-4 doses, for children – 40 mg/kg in 3-4 doses.
The maximum daily dose for adults with intravenous administration is 3-4 g.
Adverse Reactions
From the cardiovascular system: cardiac arrest, flushing, decreased blood pressure, shock (these symptoms are mainly associated with rapid infusion of the drug).
From the hematopoietic system: neutropenia, eosinophilia, thrombocytopenia, agranulocytosis.
From the digestive system: nausea.
From the urinary system: interstitial nephritis, changes in renal function tests, impaired renal function.
From the sensory organs: vertigo, ringing in the ears, ototoxic effects.
Dermatological reactions: exfoliative dermatitis, benign bullous dermatosis, pruritic dermatosis, rash.
Allergic reactions: urticaria, Stevens-Johnson syndrome, toxic epidermal necrolysis, vasculitis. Anaphylactoid reactions are possible during or shortly after too rapid infusion of vancomycin.
Other: chills, drug fever, tissue necrosis at injection sites, pain at injection sites, thrombophlebitis. With rapid intravenous administration, the development of the “red neck syndrome”, associated with histamine release, is possible: erythema, skin rash, redness of the face, neck, upper half of the torso, arms, rapid heartbeat, nausea, vomiting, chills, fever, fainting.
Contraindications
Acoustic neuritis, severe renal impairment, first trimester of pregnancy, lactation period (breastfeeding), hypersensitivity to vancomycin.
Use in Pregnancy and Lactation
Use in the first trimester of pregnancy is contraindicated due to the risk of nephro- and ototoxicity. The use of vancomycin in the second and third trimesters is possible only for vital indications.
If it is necessary to use during lactation, breastfeeding should be discontinued.
Use in Renal Impairment
Contraindicated in severe renal impairment.
Use with caution in mild and moderate renal impairment.
Pediatric Use
When used in newborns, it is necessary to monitor the plasma concentration of vancomycin.
Geriatric Use
When used in elderly patients, it is necessary to monitor the plasma concentration of vancomycin.
Special Precautions
Use with caution in mild and moderate renal impairment, hearing impairment (including in the anamnesis), in the second and third trimesters of pregnancy. During treatment, patients with kidney disease and/or damage to the VIII pair of cranial nerves should undergo monitoring of renal function and hearing.
Intramuscular administration of vancomycin is not allowed due to the high risk of tissue necrosis.
When used in newborns or elderly patients, it is necessary to monitor the plasma concentration of vancomycin.
Drug Interactions
Simultaneous use of vancomycin and local anesthetics may lead to the development of erythema, histamine-like flushing, and anaphylactic shock.
With simultaneous use of vancomycin with aminoglycosides, amphotericin B, cisplatin, cyclosporine, furosemide, polymyxins, an increase in oto- and nephrotoxic effects is noted.
Storage Conditions
Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.
Dispensing Status
Rx Only
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical DisclaimerBrand (or Active Substance), Marketing Authorisation Holder, Dosage Form
Lyophilizate for concentrate for solution for infusion and solution for oral administration 500 mg: vial 1, 10 or 50 pcs.
Lyophilizate for concentrate for solution for infusion and solution for oral administration 1000 mg: vial 1, 10 or 50 pcs.
Marketing Authorization Holder
AlTro, LLC (Russia)
Manufactured By
Reyoung Pharmaceutical, Co., Ltd. (China)
Dosage Forms
 |
Vancomycin | Lyophilizate for concentrate for solution for infusion and solution for oral administration 500 mg: vial 1, 10 or 50 pcs. |
| Lyophilizate for concentrate for solution for infusion and solution for oral administration 1000 mg: vial 1, 10 or 50 pcs. |
Dosage Form, Packaging, and Composition
Lyophilizate for concentrate for solution for infusion and solution for oral administration white or almost white with a pinkish or yellowish, or light brown tint.
| 1 vial | |
| Vancomycin (as hydrochloride) | 500 mg |
Vials of colorless glass with a capacity of 10 ml (1) – cardboard packs.
Vials of colorless glass with a capacity of 10 ml (10) – contour packs (1) – cardboard packs.
Vials of colorless glass with a capacity of 10 ml (50) – contour packs (1) – cardboard packs.
Lyophilizate for concentrate for solution for infusion and solution for oral administration white or almost white with a pinkish or yellowish, or light brown tint.
| 1 vial | |
| Vancomycin (as hydrochloride) | 1000 mg |
Vials of colorless glass with a capacity of 20 ml (1) – cardboard packs.
Vials of colorless glass with a capacity of 20 ml (10) – contour packs (1) – cardboard packs.
Vials of colorless glass with a capacity of 20 ml (50) – contour packs (1) – cardboard packs.
Lyophilizate for solution for infusion and oral administration 1000 mg: vial 1 pcs.
Marketing Authorization Holder
Belmedpreparaty RUP (Republic of Belarus)
Dosage Form
|
Vancomycin | Lyophilizate for solution for infusion and oral administration 1000 mg: vial 1 pcs. |
Dosage Form, Packaging, and Composition
Lyophilizate for solution for infusion and oral administration in the form of a powder or porous mass from white to white with a grayish or pinkish tint.
| 1 vial | |
| Vancomycin hydrochloride (in terms of Vancomycin) | 1000 mg |
1000 mg – vials of colorless glass (1) – cardboard packs.
Powder for solution for infusion and oral administration 500 mg: vials 1, 5, or 10 pcs.; vial 1 pc. with solvent
Powder for solution for infusion and oral administration 1000 mg: vial 1, 5, or 10 pcs.; vial 1 pc. with solvent
Marketing Authorization Holder
Velpharm, LLC (Russia)
Dosage Forms
|
Vancomycin | Powder for solution for infusion and oral administration 500 mg: vials 1, 5, or 10 pcs.; vial 1 pc. with solvent |
| Powder for solution for infusion and oral administration 1000 mg: vial 1, 5, or 10 pcs.; vial 1 pc. with solvent |
Dosage Form, Packaging, and Composition
Powder for solution for infusion and oral administration white or white with a pinkish, or yellowish, or light brown tint.
| 1 vial | |
| Vancomycin hydrochloride | 512.7 mg, |
| Equivalent to vancomycin content | 500 mg |
Vials of colorless glass (1) – cardboard packs with partitions.
Vials of colorless glass (5) – cardboard packs with partitions.
Vials of colorless glass (10) – cardboard packs with partitions.
Vials of colorless glass (1) in a set with solvent (“Water for injections” amp. 5 ml 2 pcs. or 10 ml 1 pc.) – cardboard packs with partitions.
Vials of colorless glass (1) in a set with solvent (“Water for injections” amp. 5 ml 2 pcs. or 10 ml 1 pc.) – contour cell packs (1) – cardboard packs.
Powder for solution for infusion and oral administration white or white with a pinkish, or yellowish, or light brown tint.
| 1 vial | |
| Vancomycin hydrochloride | 1025.4 mg, |
| Equivalent to vancomycin content | 1000 mg |
Vials of colorless glass (1) – cardboard packs with partitions.
Vials of colorless glass (5) – cardboard packs with partitions.
Vials of colorless glass (10) – cardboard packs with partitions.
Vials of colorless glass (1) in a set with solvent (“Water for injections” amp. 10 ml 2 pcs. or 20 ml 1 pc.) – cardboard packs with partitions.
Vials of colorless glass (1) in a set with solvent (“Water for injections” amp. 10 ml 2 pcs. or 20 ml 1 pc.) – contour cell packs (1) – cardboard packs.
Powder for solution for infusion and oral administration 500 mg: vial 1, 10 or 50 pcs.
Powder for solution for infusion and oral administration 1 g: vial 1, 10 or 50 pcs.
Marketing Authorization Holder
Kraspharma, PJSC (Russia)
Dosage Forms
|
Vancomycin | Powder for solution for infusion and oral administration 500 mg: vial 1, 10 or 50 pcs. |
| Powder for solution for infusion and oral administration 1 g: vial 1, 10 or 50 pcs. |
Dosage Form, Packaging, and Composition
Powder for solution for infusion and solution for oral administration
| 1 vial | |
| Vancomycin hydrochloride | 0.513 g |
| Equivalent to vancomycin content | 0.5 g |
500 mg – vials (1) – cardboard packs.
500 mg – vials (10) – cardboard packs.
500 mg – vials (50) – cardboard packs.
Powder for solution for infusion and solution for oral administration
| 1 vial | |
| Vancomycin hydrochloride | 1.026 g |
| Equivalent to vancomycin content | 1 g |
1 g – vials (1) – cardboard packs.
1 g – vials (10) – cardboard packs.
1 g – vials (50) – cardboard packs.
Lyophilizate for solution for infusion and oral administration 0.5 g: vial 1 pcs. with solvent or 10 pcs.
Lyophilizate for solution for infusion and oral administration 1 g: vial 1 pcs. with solvent or 10 pcs.
Marketing Authorization Holder
Kraspharma, PJSC (Russia)
Dosage Forms
|
Vancomycin | Lyophilizate for solution for infusion and oral administration 0.5 g: vial 1 pcs. with solvent or 10 pcs. |
| Lyophilizate for solution for infusion and oral administration 1 g: vial 1 pcs. with solvent or 10 pcs. |
Dosage Form, Packaging, and Composition
Lyophilizate for solution for infusion and oral administration in the form of a lyophilized mass from white to white with a yellowish or pinkish tint.
| 1 vial | |
| Vancomycin hydrochloride | 0.5126 g |
| Equivalent to vancomycin content | 0.5 g |
0.5 g – vials of colorless glass (1) – cardboard packs.
0.5 g – vials of colorless glass (5) – cardboard packs.
0.5 g – vials of colorless glass (10) – cardboard packs.
Lyophilizate for solution for infusion and oral administration in the form of a powder or porous mass from white to white with a pinkish or light brown tint.
| 1 vial | |
| Vancomycin hydrochloride | 1.026 g |
| Equivalent to vancomycin content | 1 g |
1 g – vials of colorless glass (1) – cardboard packs.
1 g – vials of colorless glass (10) – cardboard packs.
1 g – vials of colorless glass (50) – cardboard boxes (for hospitals).
1 g – vials of colorless glass (1) (1-50 pcs.) – cardboard boxes (for hospitals).
1 g – vials of colorless glass (1) (in a set with solvent 10 ml amp. 2 pcs. ) – cardboard packs.
Lyophilizate for solution for infusion and oral administration 500 mg: vial 1, 5 or 10 pcs.
Lyophilizate for solution for infusion and oral administration 1000 mg: vial 1, 5 or 10 pcs.
Marketing Authorization Holder
Promomed Rus LLC (Russia)
Manufactured By
Biokhimik, JSC (Russia)
Dosage Forms
|
Vancomycin | Lyophilizate for solution for infusion and oral administration 500 mg: vial 1, 5 or 10 pcs. |
| Lyophilizate for solution for infusion and oral administration 1000 mg: vial 1, 5 or 10 pcs. |
Dosage Form, Packaging, and Composition
Lyophilizate for preparation of solution for infusion and oral administration in the form of a white or white with a yellowish, pinkish or brownish tint powder or powder with fragments of a porous mass, or a dry porous mass in the form of a tablet, whole or crumbled.
| 1 vial | |
| Vancomycin hydrochloride | 512.7 mg, |
| Equivalent to vancomycin content | 500 mg |
Glass vials with a capacity of 10 ml (1) – cardboard packs.
Glass vials with a capacity of 10 ml (5) – cardboard packs.
Glass vials with a capacity of 10 ml (10) – cardboard packs.
Lyophilizate for preparation of solution for infusion and oral administration in the form of a white or white with a yellowish, pinkish or brownish tint powder or powder with fragments of a porous mass, or a dry porous mass in the form of a tablet, whole or crumbled.
| 1 vial | |
| Vancomycin hydrochloride | 1025.4 mg, |
| Equivalent to vancomycin content | 1000 mg |
Glass vials with a capacity of 20 ml (1) – cardboard packs.
Glass vials with a capacity of 20 ml (5) – cardboard packs.
Glass vials with a capacity of 20 ml (10) – cardboard packs.
Lyophilizate for preparation of solution for infusion and oral administration 0.5 g: fl. 1, 5 or 10 pcs.
Marketing Authorization Holder
Technology Lekarstv LLC (Russia)
Manufactured By
R-Pharm JSC (Russia)
Dosage Form
|
Vancomycin | Lyophilizate for preparation of solution for infusion and oral administration 0.5 g: fl. 1, 5 or 10 pcs. |
Dosage Form, Packaging, and Composition
Lyophilizate for preparation of solution for infusion and oral administration in the form of a lyophilized mass from white to white with a yellowish or pinkish tint.
| 1 vial | |
| Vancomycin (as hydrochloride) | 0.5126 g |
| Equivalent to vancomycin content | 0.5 g |
0.5 g – vials of colorless glass (1) – cardboard packs.
0.5 g – vials of colorless glass (5) – cardboard packs.
0.5 g – vials of colorless glass (10) – cardboard packs.
Lyophilizate for solution for infusion 1 g: vial 1, 5 or 10 pcs.
Marketing Authorization Holder
Technology Lekarstv LLC (Russia)
Manufactured By
R-Pharm JSC (Russia)
Dosage Form
|
Vancomycin | Lyophilizate for solution for infusion 1 g: vial 1, 5 or 10 pcs. |
Dosage Form, Packaging, and Composition
Lyophilizate for preparation of solution for infusion in the form of a lyophilized mass from white to white with a yellowish or pinkish tint.
| 1 vial | |
| Vancomycin (as hydrochloride) | 1.0252 g, |
| Vancomycin | 1 g |
1 g – vials of colorless glass (1) – cardboard packs.
1 g – vials of colorless glass (5) – cardboard packs.
1 g – vials of colorless glass (10) – cardboard packs.
Powder for solution for infusion 500 mg: vials 1 or 50 pcs.
Marketing Authorization Holder
Pharmguid, CJS (Russia)
Manufactured By
Lyka Labs, Ltd. (India)
Labeled By
SKOPINSKY PHARMACEUTICAL PLANT, CJSC (Russia)
Dosage Form
|
Vancomycin | Powder for solution for infusion 500 mg: vials 1 or 50 pcs. |
Dosage Form, Packaging, and Composition
| Powder for preparation of solution for infusion | 1 vial |
| Vancomycin (as hydrochloride) | 500 mg |
500 mg – vials (1) – cardboard packs.
500 mg – vials (50) – cardboard boxes.
Powder for solution for infusion 1 g: vials 1 or 50 pcs.
Marketing Authorization Holder
Pharmguid, CJS (Russia)
Manufactured By
Lyka Labs, Ltd. (India)
Labeled By
SKOPINSKY PHARMACEUTICAL PLANT, CJSC (Russia)
Dosage Form
|
Vancomycin | Powder for solution for infusion 1 g: vials 1 or 50 pcs. |
Dosage Form, Packaging, and Composition
| Powder for preparation of solution for infusion | 1 vial |
| Vancomycin (as hydrochloride) | 1 g |
1 g – vials (1) – cardboard packs.
1 g – vials (50) – cardboard boxes.
Powder for solution for infusion and solution for oral administration 500 mg: vial 1 pc.
Powder for solution for infusion and solution for oral administration 1000 mg: vial 1 pc.
Marketing Authorization Holder
Pharmconcept, LLC (Russia)
Dosage Forms
|
Vancomycin | Powder for solution for infusion and solution for oral administration 500 mg: vial 1 pc. |
| Powder for solution for infusion and solution for oral administration 1000 mg: vial 1 pc. |
Dosage Form, Packaging, and Composition
Powder for preparation of solution for infusion and solution for oral administration white or almost white with a pinkish or light brown tint.
| 1 vial | |
| Vancomycin hydrochloride | 513 mg, |
| Equivalent to vancomycin content | 500 mg |
Glass vials (1) – cardboard packs.
Powder for preparation of solution for infusion and solution for oral administration white or almost white with a pinkish or light brown tint.
| 1 vial | |
| Vancomycin hydrochloride | 1026 mg, |
| Equivalent to vancomycin content | 1000 mg |
Glass vials (1) – cardboard packs.
Powder for solution for infusion 500 mg: vial 1 pcs.
Marketing Authorization Holder
Elfa SPC, JSC (Russia)
Manufactured By
Ruzpharma, LLC (Russia)
Dosage Form
|
Vancomycin Elfa | Powder for solution for infusion 500 mg: vial 1 pcs. |
Dosage Form, Packaging, and Composition
Powder for preparation of solution for infusion white or white with a pinkish or yellowish or brownish tint.
| 1 vial | |
| Vancomycin (as hydrochloride) | 500 mg |
10 ml – vials (1) – cardboard packs.
10 ml – vials (10) – cardboard boxes (for hospitals).
10 ml – vials (50) – cardboard boxes (for hospitals).
Powder for solution for infusion 1000 mg: vial 1 pc.
Marketing Authorization Holder
Elfa SPC, JSC (Russia)
Manufactured By
Ruzpharma, LLC (Russia)
Dosage Form
|
Vancomycin Elfa | Powder for solution for infusion 1000 mg: vial 1 pc. |
Dosage Form, Packaging, and Composition
Powder for preparation of solution for infusion white or white with a pinkish or yellowish or brownish tint.
| 1 vial | |
| Vancomycin (as hydrochloride) | 1000 mg |
20 ml – vials (1) – cardboard packs.
20 ml – vials (10) – cardboard boxes (for hospitals).
20 ml – vials (50) – cardboard boxes (for hospitals).
Lyophilizate for the preparation of solution for infusion 500 mg: vial 1 or 5 pcs.
Marketing Authorization Holder
Jodas Expoim, Pvt. Ltd. (India)
Manufactured By
Bryntsalov-A, JSC (Russia)
Dosage Form
|
Vancomycin J | Lyophilizate for the preparation of solution for infusion 500 mg: vial 1 or 5 pcs. |
Dosage Form, Packaging, and Composition
| Lyophilizate for preparation of solution for infusion | 1 vial |
| Vancomycin | 500 mg |
500 mg – vials (1) – cardboard packs.
500 mg – vials (5) – cardboard packs.
Lyophilizate for solution for infusion 1 g: vial 1 or 5 pcs.
Marketing Authorization Holder
Jodas Expoim, Pvt. Ltd. (India)
Manufactured By
Bryntsalov-A, JSC (Russia)
Dosage Form
|
Vancomycin J | Lyophilizate for solution for infusion 1 g: vial 1 or 5 pcs. |
Dosage Form, Packaging, and Composition
| Lyophilizate for preparation of solution for infusion | 1 vial |
| Vancomycin | 1 g |
1 g – vials (1) – cardboard packs.
1 g – vials (5) – cardboard packs.
Lyophilizate for solution for infusion and oral administration 500 mg: vial in set with solvent.
Lyophilisate for preparation of solution for infusion and oral administration 1000 mg: vial in set with solvent.
Marketing Authorization Holder
Jodas Expoim, Pvt. Ltd. (India)
Manufactured By
Stanex Drugs & Chemicals Pvt. Ltd. (India)
Dosage Forms
|
Vancomycin Jodas | Lyophilizate for solution for infusion and oral administration 500 mg: vial in set with solvent. |
| Lyophilisate for preparation of solution for infusion and oral administration 1000 mg: vial in set with solvent. |
Dosage Form, Packaging, and Composition
Lyophilizate for preparation of solution for infusion and oral administration in the form of a powder or porous mass from white to white with a pinkish or brownish tint; powder clumping is allowed and does not affect solubility and quality.
| 1 vial | |
| Vancomycin hydrochloride | 512.7 mg, |
| Equivalent to vancomycin content | 500 mg |
500 mg – vials (1) + 1 amp. with solvent – cardboard packs.
500 mg – vials (5) + 5 amp. with solvent – trays (1) – cardboard packs.
500 mg – vials (5) + 5 amp. with solvent – trays (2) – cardboard packs.
Lyophilizate for preparation of solution for infusion and oral administration in the form of a powder or porous mass from white to white with a pinkish or brownish tint; powder clumping is allowed and does not affect solubility and quality.
| 1 vial | |
| Vancomycin hydrochloride | 1025.4 mg, |
| Equivalent to vancomycin content | 1000 mg |
1000 mg – vials (1) + 2 amp. with solvent – cardboard packs.
1000 mg – vials (5) + 10 amp. with solvent – trays (1) – cardboard packs.
1000 mg – vials (5) + 10 amp. with solvent – trays (2) – cardboard packs.
Powder for concentrate for solution for infusion and solution for oral administration 500 mg
Powder for concentrate for solution for infusion and solution for oral administration 1000 mg
Marketing Authorization Holder
Binnopharm Group LLC (Russia)
Manufactured By
Sintez PJSC (Russia)
Dosage Forms
|
Vancomycin-Akos | Powder for concentrate for solution for infusion and solution for oral administration 500 mg |
| Powder for concentrate for solution for infusion and solution for oral administration 1000 mg |
Dosage Form, Packaging, and Composition
Powder for preparation of concentrate for preparation of solution for infusion and solution for oral administration
| 1 vial | |
| Vancomycin (as hydrochloride) | 500 mg |
500 g – vials – cardboard packs – By prescription
500 g – vials (10 pcs.) – cardboard packs – By prescription
500 g – vials (50 pcs.) – cardboard boxes – for hospitals
Powder for preparation of concentrate for preparation of solution for infusion and solution for oral administration
| 1 vial | |
| Vancomycin (as hydrochloride) | 1000 mg |
1000 mg – vials – cardboard packs – By prescription
1000 mg – vials (10 pcs.) – cardboard packs – By prescription
1000 mg – vials (50 pcs.) – cardboard boxes – for hospitals
Powder for concentrate for solution for infusion and solution for oral administration 500 mg: vial 1 or 5 pcs.
Powder for concentrate for solution for infusion and solution for oral administration 1000 mg: vial 1 or 5 pcs.
Marketing Authorization Holder
Triplepharm JV LLC (Republic of Belarus)
Dosage Forms
|
Vancomycin-TF | Powder for concentrate for solution for infusion and solution for oral administration 500 mg: vial 1 or 5 pcs. |
| Powder for concentrate for solution for infusion and solution for oral administration 1000 mg: vial 1 or 5 pcs. |
Dosage Form, Packaging, and Composition
Powder for preparation of concentrate for preparation of solution for infusion and solution for oral administration white or almost white; hygroscopic.
| 1 vial | |
| Vancomycin hydrochloride | 513 mg, |
| In terms of Vancomycin | 500 mg |
| Equivalent to | Not less than 525000 IU |
500 mg – vials of colorless glass (1) – carton packs.
500 mg – vials of colorless glass (5) – carton packs.
Powder for concentrate for solution for infusion and oral solution white or almost white; hygroscopic.
| 1 vial | |
| Vancomycin hydrochloride | 1026 mg |
| In terms of Vancomycin | 1000 mg, |
| Equivalent to | Not less than 1050000 IU |
1000 mg – vials of colorless glass (1) – carton packs.
1000 mg – vials of colorless glass (5) – carton packs.
![Vancomycin [Lyophilisate, Powder] 1](https://www.medixlife.com/wp-content/uploads/Medixlife_favi_512.png "Vancomycin [Lyophilisate, Powder] 2")